DCGI approves Phase 2, 3 clinical trials of COVAXIN on children aged 2 to 18 years

"The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on May 12, 2021," the ministry said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3w0dsay
via IFTTT